Have a feature idea you'd love to see implemented? Let us know!

GALT Galectin Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GALT

Price (delayed)

$0.9

Market cap

$56.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$133.98M

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a ...

Highlights
Galectin Therapeutics's EPS has increased by 8% QoQ and by 3.9% YoY
The company's net income rose by 6% QoQ
GALT's equity has dropped by 79% year-on-year and by 12% since the previous quarter
The debt has soared by 71% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.galectintherapeutics.com
Peers: MEIP MNKD MNOV NERV

Key stats

What are the main financial stats of GALT
Market
Shares outstanding
62.76M
Market cap
$56.49M
Enterprise value
$133.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Net income
-$45.08M
EBIT
-$40.42M
EBITDA
-$40.38M
Free cash flow
-$33.68M
Per share
EPS
-$0.73
EPS diluted
-$0.73
Free cash flow per share
-$0.54
Book value per share
-$1.51
Revenue per share
$0
TBVPS
$0.47
Balance sheet
Total assets
$28.97M
Total liabilities
$121.45M
Debt
$104.55M
Equity
-$94.2M
Working capital
$3.41M
Liquidity
Debt to equity
-1.11
Current ratio
1.13
Quick ratio
1.07
Net debt/EBITDA
-1.92
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-163.4%
Return on equity
N/A
Return on invested capital
-55.2%
Return on capital employed
-1,088.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
7.07%
1 week
-55%
1 month
-67.51%
1 year
-44.44%
YTD
-45.78%
QTD
-67.27%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.57M
Net income
-$45.08M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 6% QoQ

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has increased by 8% QoQ and by 3.9% YoY
GALT's equity has dropped by 79% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance
GALT's ROIC is up by 44% YoY and by 17% QoQ
The ROA has grown by 25% YoY and by 12% from the previous quarter

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 76% less than its total liabilities
The total liabilities has soared by 66% YoY and by 11% from the previous quarter
Galectin Therapeutics's quick ratio has decreased by 45% YoY and by 39% QoQ
GALT's equity has dropped by 79% year-on-year and by 12% since the previous quarter
The debt has soared by 71% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.